The Shareholders Foundation announces that an investigation on behalf of current long-term investors in shares of Geron Corporation (NASDAQ:GERN) shares is ongoing over potential breaches of fiduciary duties by certain officers and directors at Geron.
Investors who purchased shares of Geron Corporation (NASDAQ:GERN) prior to March 2014 and currently hold any of those NASDAQ:GERN shares have certain options and should contact the Shareholders Foundation at email@example.com or call +1(858) 779 – 1554.
The investigation by a law firm concerns whether certain Geron Corporation (NASDAQ:GERN officers and directors breached their fiduciary duties and caused damage to the company and its shareholders.
On March 12, 2014, Geron Corporation (NASDAQ: GERN) announced that the company has received verbal notice from the U.S. Food and Drug Administration (“FDA”) that its Investigational New Drug “(IND”) application for imetelstat has been placed on full clinical hold, affecting all ongoing company-sponsored clinical trial.
On March 14, 2014 a lawsuit was filed against Geron over alleged Securities Laws Violations. the plaintiff claims that between June 16, 2013, and March 11, 2014, Geron Corporation allegedly omitted to disclose material facts showing imetelstat’s poor prospects, including that persistent low-grade liver function test (LFT) abnormalities had been observed in the Phase 2 study of imetelstat in essential thrombocythemia (ET) or polycythemia vera (PV) patients and that there was a potential risk of chronic liver injury following long-term exposure to imetelstat. Shares of Geron Corporation (NASDAQ:GERN) declined from as high as $5.86 per share in late 2013 to as low as $1.80 per share in May 2014.
Those who purchased shares of Geron Corporation (NASDAQ:GERN), have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North – Suite 423
92108 San Diego